The Notch signaling pathway represents a critical component in the molecular circuits that control cell fate during development.
Background
The Notch signaling pathway is evolutionarily conserved and the basic molecular players in this pathway are ligands (Delta and Jagged), Notch receptors, and the transcription factors (reviewed in ref. 1) . Notch is a transmembrane heterodimeric receptor and there are four distinct members (Notch1 to Notch4) in humans and rodents. In a physiologic condition, binding of the Notch ligand to its receptor initiates Notch signaling by releasing the intracellular domain of the Notch receptor (Notch-IC) through a cascade of proteolytic cleavages by both a-secretase (also called tumor necrosis factor-a-converting enzyme) and g-secretase (Fig. 1A) . The released intracellular Notch-IC then translocates into the nucleus where it modulates gene expression primarily by binding to a ubiquitous transcription factor, CBF1, suppressor of hairless, Lag-1 (CSL). This binding recruits transcription activators to the CSL complex and converts it from a transcriptional repressor into an activator, which turns on several downstream effectors. The physiologic functions of Notch signaling are multifaceted, including maintenance of stem cells, specification of cell fate, and regulation of differentiation in development as well as in oncogenesis (2, 3) .
In cancers, molecular genetic alterations, such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for constitutive activation of Notch pathway. Despite the different mechanisms, they all result in increased levels of intracellular Notch-IC. The oncogenic potential of Notch was first discovered in human T-cell acute lymphoblastic leukemia (T-ALL). While Notch1 signaling is essential for normal development of T-cell progenitors (4), constitutive activation of Notch1 signaling due to molecular genetic alterations is associated with T-ALL. For example, interstitial deletions of the extracellular portion of human Notch1 due to (7;9) chromosomal translocation are associated with f10% of T-ALL cases and activating point mutations of Notch1 are present in f50% of T-ALL cases (5, 6) . Constitutive activation of nuclear factor-nB and formation of T-cell leukemia/lymphoma were observed in a Notch-IC transgenic mouse model (7), which indicates a causal role of Notch activation in T-ALL development. In non-small cell lung cancer, chromosomal translocation (15;19) has been identified in a subset of tumors, and the translocation is thought to elevate Notch3 transcription in tumors (8) . In ovarian cancer, Notch3 gene amplification was found to occur in f19% of tumors, and overexpression of Notch3 was found in more than half of the ovarian serous carcinomas (9) . Similarly, Notch signaling activation has been shown in the development of breast cancer. In animal models, constitutively active Notch4 expression causes mammary tumors in mice (10) and Notch1-activating mutations contribute to the development of T-ALL. A recent study further shows that overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse breast tumors (11) . Overexpression of Notch3 is sufficient to induce choroid plexus tumor formation in a mouse model, suggesting a role of Notch3 in the development of certain types of brain tumors (12) .
;-Secretase as a Key Mediator of Notch Signaling
Because the Notch-IC signaling plays an important role in cancer development, it is plausible that targeting the Notch signaling steps, including receptor/ligand binding, release of Notch-IC, interaction of Notch-IC and downstream targets, as well as Notch-IC protein stability, can have antitumor effects (13, 14) . Currently, one of the emerging approaches for blocking Notch signaling is to suppress the proteolytic step that leads to the generation of intracellular Notch-IC (Fig. 1B) . On ligand binding, Notch receptors undergo a series of programmed proteolytic events, first by a-secretase at the extracellular surface, which leads to liberation of the extracellular fragment, and then by intramembranous cleavage mediated by g-secretase. Notch-IC is then released from the inner surface of cell membrane and is translocated into nucleus where it activates transcription of the target genes. The proteolytic events in Notch signaling activation are comparable with the processes involving amyloid precursor protein (APP) cleavage (Fig. 1B) , in which sequential cleavages by h-secretase and g-secretase release the amyloid h-peptide (the precursor of amyloid plaques found in the brain of Alzheimer's disease).
g-Secretase is a large protease complex and is composed of a catalytic subunit (presenilin-1 or presenilin-2) and accessory subunits (Pen-2, Aph1, and nicastrin). All these subunits contain transmembrane domains and thus they are membrane proteins. The pivotal role of g-secretase in the Notch activation cascade has been well shown in an elegant knockin experiment, showing that introduction of a single point mutation near the transmembrane cleavage site in Notch1 molecules results in an embryonic lethality in mice, which is similar to the effects observed in Notch1 Figure 1 . An overview of Notch signaling and proteolytic processing. Top, Notch receptor is a cell surface protein. Interaction with the Notch ligand, such as Jagged, initiates proteolytic cleavage at the extracellular site by a-secretase followed by cleavage at the intracellular site by g-secretase, resulting in the release of Notch-IC from the cytoplasmic side of the cell membrane. Notch-IC is then translocated into the nucleus where it interacts with CSL and recruits coactivators (CoA) to form a transcription-activating complex. Notch-IC can be polyubiquitylated and targeted for degradation in a proteasome-dependent manner. However, the location of degradation is currently not clear. Bottom, the proteolytic events involving Notch receptor and APP are similar. APP is an integral membrane protein and is cleaved at the extracellular site by h-secretase followed by g-secretase to release Ah peptides. Ah is the major constituent of amyloid plaques and its accumulation is thought to play a central role in Alzheimer's disease. APP can be also cleaved by a-secretase and g-secretase, which leads to liberation of P3 peptides with unknown functions.
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Over the past decades, inhibitors for g-secretase have been actively investigated for their potential to block the generation of Ah peptide that is associated with Alzheimer's disease (18) . Because g-secretase inhibitors are also able to prevent Notch receptor activation, several forms of g-secretase inhibitors have been tested for antitumor effects. First, an original g-secretase inhibitor, IL-X (cbz-IL-CHO), was shown to have Notch1-dependent antineoplastic activity in Ras-transformed fibroblasts. More recently, tripeptide g-secretase inhibitor (z-Leu-leu-Nle-CHO) was reported to suppress tumor growth in cell lines and/or xenografts in mice from melanoma and Kaposi sarcoma (19) . Treatment with dipeptide g-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-Sphenylglycine t-butyl ester (DAPT) also resulted in a marked reduction in medulloblastoma growth and induced G 0 -G 1 cell cycle arrest and apoptosis in a T-ALL animal model (20, 21) . Another g-secretase inhibitor, dibenzazepine, has been shown to inhibit epithelial cell proliferation and induce goblet cell differentiation in intestinal adenomas in Apc À/À (min) mice (22) . More recently, functional inactivation of Notch3 either by tripeptide g-secretase inhibitor or Notch3-specific small interfering RNA results in suppression of cell proliferation and induction of apoptosis in the tumor cell lines that overexpressed Notch3 but not in those with minimal amounts of Notch3 expression (9) . Futhermore, a phase I clinical trial for a Notch inhibitor, MK0752 (developed by Merck, Whitehouse Station, NJ), has been launched for relapsed or refractory T-ALL patients and advanced breast cancers. 1 As discussed above, Notch signaling and APP metabolism are triggered by the similar proteolytic process; it is foreseeable that g-secretase inhibitors that are currently tested in clinical trials for Alzheimer's disease may be applicable to treat neoplastic diseases, especially those tumors known to harbor constitutive Notch activation. Besides the evidence of g-secretase inhibitors in directly inactivating Notch signaling on cancer cells, g-secretase inhibitors may also suppress angiogenesis in solid tumors by interfering in the cross-talk between the tumor and vasculature through the Notch signaling (23) .
The exciting studies summarized above strongly suggest a potential clinical application of g-secretase inhibitors in cancer therapeutics. However, one of the major challenges on the way toward this goal is the untoward side effects associated with the inhibitors, especially the cytotoxicity in the gastrointestinal tract (24) , which can be exacerbated by conventional chemotherapeutic drugs. Therefore, balancing efficacy and toxicity of g-secretase inhibitors must be considered in future clinical applications. The possible mechanisms underlying the unwanted cytotoxicity are multifactorial. First, Notch signaling pathway is known to widely participate in cellular physiology in normal tissues, including hematopoiesis and maintenance of arterial smooth muscle (25) ; therefore, it is plausible that inactivation of g-secretase may lead to dysfunction of vital organs. Second, it is likely that g-secretase inhibitors do not exclusively target the Notch signaling pathways. This is because g-secretase has many substrates in addition to Notch receptors, such as several Notch ligands, ErbB4, syndecan (an extracellular matrix), and CD44 (1). Additionally, g-secretase inhibitors may target proteases other than g-secretase. As proteases participate in a wide variety of cellular functions, g-secretase inhibitors may have other widespread adverse effects in vivo. Some of the concerns of the nonselectivity of the inhibitors will be addressed based on the results of the ongoing clinical trials. Nevertheless, it may prove possible to identify a therapeutic window, in which partial inhibition of g-secretase is sufficient to suppress Notch signaling in cancer cells, whereas the dosage will not significantly affect the functions in normal tissues. It is thought that the differential killing between cancer and normal cells can be exaggerated in treating those tumors with constitutive Notch activation, in which cancer cells are ''addicted'' to the Notch signaling.
Implications and Future Directions
The findings discussed above have at least two major biological and clinical implications. First, like wingless (wnt) and Hedgehog (shh), the Notch signaling pathway is important in controlling both developmental processes and tumorigenesis. Tumor cells sabotage the Notch signaling pathway for tumor initiation and/or progression through constitutive activation by ways of chromosomal translocation, point mutation, gene amplification, and other epigenetic events. Second, recent studies suggest that one of the most promising targets in inactivating the Notch signaling is g-secretase complex, the molecular switch for Notch signaling activation. Recently, there has been an increased enthusiasm in targeting this pathway using g-secretase inhibitors for new cancer therapeutics because accumulating preclinical studies have shown that g-secretase inhibitors hold promise as a new target-based therapy for those tumors with Notch activation. However, before Notchbased therapy becomes a reality, future studies should primarily focus on the issues of target specificity and address the possible side effects that may affect cancer patients who receive this new treatment regimen. Furthermore, the clinical promise of g-secretase inhibitors in cancer therapeutics depends on careful correlation studies between the molecular genetic alterations in the Notch gene (e.g., mutations and gene amplification) and clinical response to g-secretase inhibitors. To maximize the therapeutic effects (together with conventional therapeutics) and minimize the adverse side effects in cancer patients, it is essential to show the ''tumor dependency'' of Notch activation experimentally and clinically. Despite several challenges on the way, it is expected that in the coming years, there will be substantial efforts in identifying new specific g-secretase inhibitors and in opening new clinical trials to test the potential of this new line of cancer therapeutic agents.
